SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing downward price pressure driven by investor disappointment regarding the efficacy data for its sonelokimab therapy in psoriatic arthritis, as well as concerns over the company's decision to pursue a solo commercialization strategy involving potential share dilution. While some traders view the current stock price as an attractive buying opportunity due to the company's strong cash position and the upcoming FDA filing for hidradenitis suppurativa, others are skeptical of management's communication and the drug's ability to compete in a crowded market.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS shares experienced downward pressure alongside widespread community debate triggered by third-party survival models shared on social media, which challenged the previously high success expectations for the REGAL trial. While some traders interpreted the decline as a coordinated manipulation effort to shake out weak hands, others viewed it as a necessary rebalancing, with many long-term shareholders emphasizing that the core clinical thesis and trial dynamics remain unchanged.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently experiencing high volatility driven by speculation regarding potential peptide product launches and broader global expansion, alongside community debate over short interest and institutional activity. Investors remain divided, with some highlighting the company's long-term growth potential and data-driven platform, while others focus on regulatory risks and intense fluctuations in trading volume.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to significant community backlash and price decline following the company's announcement of a new $1 billion at-the-market equity offering program. Traders are debating the necessity of this dilution given the company's existing cash balance, while expressing frustration over recent insider selling and the lack of immediate commercial revenue.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is trading lower following a downgrade by UBS, which cited concerns regarding a lengthy project build timeline, limited customer commitments, and projected future cash burn. While retail traders continue to debate the company's long-term commercial execution and project viability, many market participants view the pullback as an overreaction to analyst sentiment rather than a fundamental change in the sector's nuclear power thesis.

Amplify Commodity Trust - Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF

Breakwave Tanker Shipping ETF is trending as traders react to its significant year-to-date gains and ongoing geopolitical instability in the Middle East, particularly around the Strait of Hormuz. Community discussion centers on the potential for continued upside driven by shipping rate volatility and the scarcity of tanker capacity, alongside debate regarding the risks of entering the trade at current parabolic price levels.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

The conversation surrounding Onyxcoin is heavily polarized, with many traders labeling the asset a "pump and dump" scheme due to consistent price volatility and skepticism regarding its leadership. Conversely, some community members remain bullish, focusing on technical developments like the Onyx Mesh infrastructure, ongoing staking rewards, and potential institutional adoption through the integration of Chain's technology.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The energy sector is trending due to rising crude prices driven by escalating tensions in the Middle East and concerns over supply disruptions at the Strait of Hormuz. While some traders are expressing uncertainty and debating the impact of ongoing geopolitical conflict and potential diplomatic negotiations on future performance, the sector continues to show relative strength with significant year-to-date gains.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is garnering attention as investors debate whether the recent underperformance of mega-cap tech stocks represents a healthy rotational correction or a structural breakdown. Traders are closely monitoring key support levels and moving averages while weighing the impact of hyperscaler capital expenditure spending against shifting market leadership.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

The stock is trending due to speculative momentum and increased volatility surrounding the upcoming Clarity Act vote, with traders debating whether potential regulatory clarity will drive institutional adoption of stablecoins or if increasing competition from major banks will compress margins. Community sentiment remains polarized, with bulls pointing to the company's expanding infrastructure and institutional partnerships, while bears warn of valuation concerns and the threat of bank-led stablecoin alternatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-timeread more...

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.read more...

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Did OTLK Stock Crash In Pre-Market Today?

Equity

Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates

IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

• Reported GAAP EPS of -$0.15 up 72.73% YoY
• Reported revenue of $0.01M down -99.40% YoY

Outlook Therapeutics reported a significant year-over-year revenue decline to $9 thousand, a persistent net loss of $20.3 million, and exposure to unpredictable macroeconomic risks and ongoing global conflicts for Outlook Therapeutics.

Outlook Therapeutics achieved FDA approval for LYTENAVA, which the company expects will drive a significant market opportunity with potential for over $500 million in annual U.S. sales by 2030 for Outlook Therapeutics.

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Outlook Therapeutics Inc

Extremely Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Current Price	$0.66
Prev Close	$0.6612
Open	$0.67
Dividend Yield	0.00%
50-Day Moving Average	$1.02
Beta	0.87
Avg. Volume	22.28M
PE Ratio	-0.60

52-Week High	$2.54
52-Week Low	$0.1611
Market Capitalization	$160.97M
EPS (Annual)	-$1.79
Price to Book	-11.88
Revenue Per Employee	$83,149.12

Feed

News

Sentiment

Earnings

Fundamentals

Info

OTLK Fundamentals